Naganuma, Atsushi
Chayama, Kazuaki
Notsumata, Kazuo
Gane, Edward
Foster, Graham R.
Wyles, David
Kwo, Paul
Crown, Eric
Bhagat, Abhi
Mensa, Federico J.
Otani, Tetsuya
Larsen, Lois
Burroughs, Margaret
Kumada, Hiromitsu
Article History
Received: 13 September 2018
Accepted: 1 March 2019
First Online: 13 March 2019
Compliance with ethical standards
:
: Atsushi Naganuma and Kazuo Notsumata have nothing to disclose. Kazuaki Chayama received research funding from AbbVie, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Toray Industries, Inc. and received payment for lectures from AbbVie, Bristol-Myers Squibb, Gilead, and MSD. Edward Gane is an advisor for AbbVie, Alnylam, Arbutus, Assembly, Arrowhead, Enanta, Gilead Sciences, Janssen, Merck, Novartis, Novira, Roche, and VIR, and participated in speakers’ bureaus for AbbVie, Gilead Sciences. Graham Foster received grants from AbbVie, Gilead, and Merck, and consulted and participated in speakers’ bureaus for AbbVie, MSD, and Gilead. David Wyles received research funding (paid to his institution) from AbbVie, Gilead and Merck, and served as consultant to AbbVie, Gilead and Merck. Paul Kwo participated on advisory committees or review panels for AbbVie, Abbott, Merck, Gilead, Bristol-Meyers Squibb, Janssen, Alnylam, and Inovio, and received grant/research support from AbbVie, Merck, Bristol-Meyers Squibb, Janssen, Gilead, Merck, and Conatus. Eric Crown, Abhi Bhagat, Margaret Burroughs, Federico Mensa, Tetsuya Otani, and Lois Larsen are employees and may hold stock or options. Hiromitsu Kumada received payment for lectures from AbbVie GK, MSD, Dainippon Sumitomo Pharma, Bristol-Myers Squibb, and Gilead.